India Fast-Tracks Domestic Isotope Infrastructure in Major Push for Precision Cancer Care

NEW DELHI — In a bid to strengthen national cancer care capabilities and curb reliance on foreign medical imports, the Government of India has unveiled a comprehensive expansion of its nuclear medicine ecosystem. The initiative spans state-of-the-art diagnostic imaging, targeted molecular radiotherapies, and the construction of a dedicated Isotope Production Reactor (IPR) in Visakhapatnam.

The announcement was confirmed in a written statement to the Lok Sabha by Dr. Jitendra Singh, Union Minister of State for the Prime Minister’s Office, Personnel, Public Grievances and Pensions, Atomic Energy and Space. The initiative leverages institutional expertise across the Department of Atomic Energy (DAE)—including the Bhabha Atomic Research Centre (BARC), the Variable Energy Cyclotron Centre (VECC), and the Tata Memorial Centre (TMC).

Bridging the Supply Gap: The Visakhapatnam Isotope Production Reactor

At the heart of the national strategy is the establishment of a dedicated Isotope Production Reactor (IPR) at BARC, Visakhapatnam. Historically, nuclear medicine centers in India have relied on dual-use research reactors and medical cyclotrons, supplemented by radioisotopes recovered from High-Level Liquid Waste (HLLW) reprocessing—such as Ruthenium-106, Caesium-137, and Strontium-90 (which decays into Yttrium-90).

While cyclotrons like the 30 MeV medical facility at VECC in Kolkata regularly distribute diagnostic radiopharmaceuticals to regional hospitals, domestic demand frequently outstrips supply.

[Domestic Cyclotrons & Reactors] ──┐
                                  ├──► Current Supply (High Import Dependence)
[HLLW Waste Reprocessing] ────────┘

[Dedicated Visakhapatnam IPR] ───────► Future Supply Goal (Self-Reliance & Export Capability)

By establishing a facility built exclusively for medical isotope synthesis, India aims to eliminate supply chain bottlenecks for critical diagnostic and therapeutic agents. Health economists estimate that localizing primary production could lower clinical costs for end-stage targeted therapies by 30% to 50%, transforming access for lower- and middle-income demographics.

Precision Diagnostics: Seeing Cancer at the Cellular Level

Modern oncology relies heavily on functional imaging—techniques that visualize metabolic activity rather than structural changes alone. Under the expansion framework, facilities led by the Tata Memorial Centre (TMC) are scaling up two primary nuclear imaging pipelines:

1. Positron Emission Tomography-Computed Tomography (PET-CT)

PET-CT combines functional radiotracer mapping with structural anatomical scans.

• Fluorodeoxyglucose ($^{18}\text{F-FDG}$): A radiolabeled sugar molecule absorbed rapidly by high-metabolism malignant cells. It remains the gold standard for staging lung carcinoma, esophageal cancer, breast cancer, and lymphomas.

• Gallium-68 ($\text{Ga-68}$) Radiotracers: In-house radiopharmacy units produce $\text{Ga-68 DOTANOC}$ to map neuroendocrine tumors and $\text{Ga-68 FAPI}$ (Fibroblast Activation Protein Inhibitor) to visualize challenging stroma-heavy malignancies, such as mucinous and signet ring gastrointestinal cancers.

2. Gamma Camera Functional Imaging

Using technetium-99m ($^{99\text{m}}\text{Tc}$), clinicians conduct targeted functional mapping, including $^{99\text{m}}\text{Tc-PSMA}$ scans for prostate cancer staging and Multigated Acquisition (MUGA) scans to monitor cardiac ejection fraction in patients undergoing cardiotoxic chemotherapy.

┌─────────────────────────────────────────────────────────────────────────┐
│                    MOLECULAR DIAGNOSTIC PIPELINE                        │
├─────────────────────────┬───────────────────────────────────────────────┤
│ Radiotracer / Technique │ Primary Clinical Indication                   │
├─────────────────────────┼───────────────────────────────────────────────┤
│ 18F-FDG PET-CT          │ Staging Lung, Esophageal, Breast Cancers      │
│ Ga-68 DOTANOC PET-CT    │ Somatostatin Receptor (SSTR) Mapping in NETs │
│ Ga-68 FAPI PET-CT       │ Mucinous & Signet Ring GI Malignancies        │
│ 99mTc-PSMA Scans        │ Functional Staging of Prostate Cancer         │
│ MUGA Scans              │ Quantitative Cardiac Toxicity Assessment      │
└─────────────────────────┴───────────────────────────────────────────────┘

Targeted Radionuclide Therapy: The “Theranostic” Shift

The strategy shifts treatment paradigms from systemic chemotherapy toward theranostics—a approach combining diagnostic targeting with therapeutic radiation.

“Theranostics operates on a ‘see what you treat, and treat what you see’ principle,” explains Dr. Ananya Mukherjee, a senior nuclear medicine consultant independent of the DAE project. “By tagging a targeting molecule with a diagnostic isotope like Gallium-68 first, we verify that the tumor expresses the right receptors. Then, we swap the diagnostic tag for a therapeutic beta-emitter like Lutetium-177. The medicine homes in directly on the tumor site, delivering lethal radiation to cancer cells while sparing adjacent healthy tissue.”

Step 1: DIAGNOSTIC PHASE
[ Gallium-68 ] ──attached to──► [ Target Ligand ] ──binds to──► Cancer Cell Receptor (PET Scan Visualizes Tumor)

Step 2: THERAPEUTIC PHASE
[ Lutetium-177 ] ──attached to──► [ Target Ligand ] ──binds to──► Cancer Cell Receptor (Beta Radiation Destroys Tumor)

Key therapeutic modalities highlighted in the parliamentary response include:

• Iodine-131 ($\text{I-131}$): Targeted ablation of remnant thyroid tissue and metastatic thyroid carcinoma.

• Lutetium-177 ($\text{Lu-177}$) PSMA & DOTANOC: High-precision peptide receptor radionuclide therapy (PRRT) for advanced metastatic prostate cancer and refractory neuroendocrine tumors (NETs).

• Indigenously Developed Medical Devices: Collaborative clinical translation between BARC, the Board of Radiation & Isotope Technology (BRIT), and TMC has yielded specialized tools such as $^{90}\text{Y}$ Bhabhaspheres for Trans-Arterial Radioembolization (TARE) in liver cancer, indigenous blood irradiators, and Bhabhatron teletherapy units.

To administer these high-dose unsealed radioactive sources safely, specialized infrastructure is mandatory. Facilities feature six-bedded high-dose therapy wards constructed in strict compliance with Atomic Energy Regulatory Board (AERB) safety mandates. These wards incorporate underground delay tanks that hold radiocontaminated patient liquid waste, allowing it to decay safely before environmental discharge.

Overcoming Structural Limitations and Human Resource Shortages

Despite the technical promises, medical experts caution that expanding physical infrastructure solves only half the equation. The bottleneck frequently shifts to clinical manpower and regulatory compliance.

To address these human resource constraints, the DAE and TMC have integrated specialized academic frameworks. BARC and TMC currently offer postgraduate medical doctorates (MD in Nuclear Medicine), two-year fellowships in Nuclear Theranostics, specialized Master of Science (M.Sc.) degrees in Nuclear Medicine Technology and Hospital Radiopharmacy, and Diplomas in Radiological Physics (DipRP).

                        DAE & TMC HUMAN CAPITAL PIPELINE
                                       │
         ┌─────────────────────────────┼─────────────────────────────┐
         ▼                             ▼                             ▼
  [ Clinical Care ]            [ Technical Ops ]             [ Radiation Safety ]
  • MD Nuclear Medicine        • M.Sc. NMMIT                 • DipRP (Radiological
  • Fellowship in              • M.Sc. NMT & Hospital          Physics)
    Nuclear Theranostics         Radiopharmacy

However, public health policy analysts emphasize that geographic distribution remains a hurdle. “Most advanced nuclear medicine beds are concentrated in tier-one metropolitan hubs,” notes Dr. Rajesh Kulkarni, an oncologist and healthcare logistics specialist. “Ensuring that short-half-life radiopharmaceuticals reach tier-two and tier-three regional cancer centers before decaying requires ultra-efficient cold-chain transit networks.”

What This Means for Patients

For patients navigating complex cancer diagnoses, the expansion promises several direct benefits:

1. Enhanced Early Staging: Precision imaging like $\text{Ga-68 FAPI}$ and $^{18}\text{F-FDG}$ PET-CT allows oncologists to catch micro-metastases earlier, tailoring treatment plans before invasive surgery.

2. Outpatient Targeted Therapies: Advanced therapies like $\text{Lu-177 PSMA}$ offer alternative pathways for advanced-stage prostate cancer patients who have exhausted traditional hormone or chemotherapies.

3. Improved Affordability: Domestic production of isotope generators, Bhabhaspheres, and radioprotectors via BRIT reduces dependence on expensive imported kits.

Patients seeking nuclear medicine treatments should discuss options with their attending oncologist to evaluate receptor eligibility via diagnostic PET-CT before undergoing radionuclide therapy.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Parliamentary Statement: Press Information Bureau (PIB) Delhi, Department of Atomic Energy, Government of India. Lok Sabha Written Reply on National Nuclear Medicine Expansion Programme, Released July 29, 2026.